Abstract

The mission of the Breast Oncology (BR) Program is to develop innovative approaches to describe the molecular and cellular networks underlying breast cancer susceptibility, heterogeneity, diversity, and disparities with the aim of improving outcomes for healthy women and women with breast cancer. The BR Program's work aims to reduce overdiagnosis and overtreatment through individualizing screening and treatment, and derive better outcomes at lower cost. The BR Program achieves its goals through four themes: Theme 1: Improving the Understanding of Breast Cancer Etiology in the Context of the Microenvironment Theme 2: Personalizing Screening and Diagnostics to Increase Health Care Value Theme 3: Identifying New Therapeutic Targets for High-risk Disease Theme 4: Augmenting Efficiency of Drug Development through Innovative Trial Design BR Program: Key Metrics Membership (14 departments, 3 schools) 33 Full 18 Associate 15 Cancer-relevant Funding (direct costs as of $14,454,243 05/31/2017) NCI $5,307,970 37% Peer-reviewed $4,630,302 32% Non-peer-reviewed $4,515,971 31% Cancer-relevant Publications (1/2012-7/2017) 636 Inter-programmatic 141 22% Intra-Programmatic 175 28% High-Impact 190 30% Accruals to Clinical Trials (2016) 5293 58 Therapeutic 140 31 Other Interventional 9 4 Non-interventional 5144 22

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-21
Application #
9965767
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118

  Publications

Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21

Showing the most recent 10 out of 192 publications